Profit rose 13% even as restructuring charges jumped with a planned closure
IDEX's profit rose 13%, to $144.00 M, but the quarter carried a restructuring charge of $3.40 M, against $0.10 M a year earlier. In dollars it is small, but it is 34 times the figure a year earlier. The filing ties that charge mainly to severance from employee reductions, including the anticipated closure of a facility in Health & Science Technologies. Charges like this are not new: restructuring ran at $18.30 M in the first nine months of 2025 and $13.60 M in 2026.
Profit growth had help the headline does not show. The nine-month gross margin benefited from $22.70 M of tariff refunds that cut cost of sales, and the company says that refund cash was collected in the second quarter. Selling costs fell as a share of sales as well, and the filing says proceeds from legal settlements offset part of the increase in those costs. Neither of those items appears in the headline growth figure, and both lift the margin the company reports.
What it means for a reader: quarterly profit growth is real, but restructuring is not finished, and the nine-month margin gain leans on a tariff refund the company describes as largely collected in the second quarter. The restructuring line has been charged in both years, and that is the number to watch. Will the next nine-month restructuring line come in below the $18.30 M of 2025, or will the category keep recurring under the same name?

